Volume 111, Nº 1, July 2018
DOI: http://www.dx.doi.org/10.5935/abc.20180133
VIEWPOINT
Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
Paulo Eduardo Ballvé Behr
Emilio Hideyuki Moriguchi
Iran Castro
Luiz Carlos Bodanese
Oscar Pereira Dutra
Paulo Ernesto Leães
Pedro Pimentel Filho
![](images/indications-of-pcsk9-inhibitors-for-patients-at-high-and-very-high-cardiovascular-risk.jpg)
Figure 1 – Absolute risk reduction for the same relative LDL-C level reduction from different initial LDL-C levels. (Reprint with permission from Oxford University Press).
Keywords: Cardiovascular Diseases/complications; Cardiovascular Diseases/mortality; Coronary Artery Disease; Proprotein Convertase 9; Hyperlipoproteinemia Type II; Ezetimibe, Simvastatin Drug Combination.